FDA advisory committee backs Horizon’s teprotumumab

The FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted 12-0 that the benefits of Horizon Therapeutics’ (NASDAQ:HZNP) teprotumumab outweigh the risks for the treatment of thyroid eye disease (TED).

The FDA’s action date is March 8, 2020.

Teprotumumab is a fully human monoclonal antibody that binds to (inhibits) a protein called insulin-like growth factor 1 receptor (IGF-1R). TED is a rare autoimmune disorder in which IGF-1R is overexpressed in the eye.

https://seekingalpha.com/news/3526261-fda-advisory-committee-backs-horizons-teprotumumab